CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
-6.37%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.28B
AUM Growth
+$1.28B
(-15%)
Cap. Flow
+$46.3M
Cap. Flow
% of AUM
3.62%
Top 10 Holdings %
Top 10 Hldgs %
65.3%
Holding
47
New
11
Increased
11
Reduced
7
Closed
3
Top Buys
| 1 |
Avidity Biosciences
RNA
|
$18.9M |
| 2 |
Pliant Therapeutics
PLRX
|
$17.9M |
| 3 |
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
|
$16.5M |
| 4 |
NVTA
Invitae Corporation
NVTA
|
$14.7M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$14M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$67.3M |
| 2 |
Relay Therapeutics
RLAY
|
$24.7M |
| 3 |
Exact Sciences
EXAS
|
$19.9M |
| 4 |
VERV
Verve Therapeutics
VERV
|
$17.2M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
$9.73M |
Sector Composition
| 1 | Healthcare | 98.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sarepta Therapeutics
SRPT
$1.78B
| $170M | 13.2% | 1,315,000 +90,000 | +7% | +$11.7M |
|
2
BioLife Solutions
BLFS
$1.2B
| $138M | 10.67% | 7,566,292 | – | – |
|
|
EQRX
3
DELISTED
EQRx, Inc. Common Stock
EQRX
| $97.2M | 7.53% | 39,527,669 | – | – |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $86.7M | 6.72% | 365,000 -283,000 | -44% | -$67.3M |
|
5
Illumina
ILMN
$15.8B
| $77.8M | 6.03% | 385,000 | – | – |
|
|
BPMC
6
DELISTED
Blueprint Medicines
BPMC
| $64.7M | 5.02% | 1,477,800 -222,200 | -13% | -$9.73M |
|
7
Revolution Medicines
RVMD
$7.1B
| $60.1M | 4.66% | 2,525,000 +2,700 | +0.1% | +$64.3K |
|
8
MaxCyte
MXCT
$148M
| $51.9M | 4.02% | 9,505,000 -1,230,786 | -11% | -$6.72M |
|
|
9
Relay Therapeutics
RLAY
$619M
| $45.3M | 3.51% | 3,030,648 -1,652,784 | -35% | -$24.7M |
|
|
VERV
10
DELISTED
Verve Therapeutics
VERV
| $44.3M | 3.43% | 2,290,571 -887,596 | -28% | -$17.2M |
|
11
Denali Therapeutics
DNLI
$2.23B
| $36.2M | 2.8% | 1,300,000 +305,000 | +31% | +$8.48M |
|
|
12
Pliant Therapeutics
PLRX
$101M
| $32.4M | 2.51% | 1,675,000 +925,000 | +123% | +$17.9M |
|
|
SLGC
13
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
| $31.6M | 2.45% | 12,604,275 | – | – |
|
|
14
Exact Sciences
EXAS
$8.98B
| $28M | 2.17% | 565,000 -402,000 | -42% | -$19.9M |
|
15
AbCellera Biologics
ABCL
$1.25B
| $23M | 1.78% | 2,270,000 +620,000 | +38% | +$6.28M |
|
16
Twist Bioscience
TWST
$1.63B
| $22.5M | 1.74% | 945,000 +580,000 | +159% | +$13.8M |
|
|
MRTX
17
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $21.5M | 1.67% | 475,000 +225,000 | +90% | +$10.2M |
|
18
Fate Therapeutics
FATE
$120M
| $20.7M | 1.6% | 2,050,000 | – | – |
|
|
19
Avidity Biosciences
RNA
$5.99B
| $18.9M | 1.46% | +850,000 | New | +$18.9M |
|
|
TSVT
20
DELISTED
2seventy bio
TSVT
| $17.3M | 1.34% | 1,850,000 +1,235,246 | +201% | +$11.6M |
|
|
NVTA
21
DELISTED
Invitae Corporation
NVTA
| $16.8M | 1.3% | 9,038,388 +7,912,500 | +703% | +$14.7M |
|
|
RXDX
22
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $16.5M | 1.28% | +150,000 | New | +$16.5M |
|
23
Century Therapeutics
IPSC
$42.5M
| $16.4M | 1.27% | 3,206,380 | – | – |
|
24
Absci
ABSI
$357M
| $15.5M | 1.2% | 7,363,260 -355,333 | -5% | -$746K |
|
25
Beam Therapeutics
BEAM
$1.66B
| $14.5M | 1.12% | 370,000 | – | – |
|